The invention refers to the treatment and prevention of lyso paf-mediated skin disorders with an effective amount of at least one antagonists against lyso paf receptors. Lyso paf or paf receptor antagonists were administered with or without an antagonist against production of ether phospholipids. Lyso paf antagonists are Ginkgoloides which are administered, for example, by food or topically.
This application is a Continuation-In-Part of U.S. application Ser. No. 07/969,674, filed Oct. 28, 1992, now U.S. Pat. No. 5,346,894, and Ser. No. 08/246,476, filed May. 19, 1994, now abandoned.
The present invention provides a therapeutic agent for fundamentally preventing, treating or ameliorating dermatosis, such as, non-infectious dermatosis, which include psoriasis and atopic dermatitis. The therapeutic agent comprises a glycerol derivative represented by the formula (I): ##STR1## wherein A is a group represented by the formula: ##STR2## or single bond; R.sup.1 is a group represented by the formula: ##STR3## wherein R.sup.2 is a methoxyphenyl group or methyl group, X is an atom or atomic group which may become an anion or a group represented by the formula: ##STR4## or a pharmacologically acceptable salt thereof as an active ingredient.
